Pravastatin Dosing in GFR 27
In a patient with GFR 27 mL/min/1.73 m² (severe renal impairment), start pravastatin at 10 mg once daily and do not exceed a maximum dose of 40 mg daily, with close monitoring for myopathy. 1
Initiation and Dosing
A GFR of 27 mL/min/1.73 m² classifies as severe renal impairment (CKD stage 4). The FDA label explicitly addresses this scenario:
- Starting dose: 10 mg once daily (you'll need to use a different pravastatin product initially since pravastatin tablets come in 10,20, and 40 mg strengths) 1
- Maximum dose: 40 mg once daily - do not exceed this regardless of lipid response 1
- Timing: Can be taken at any time of day, with or without food 1
The KDIGO/KDOQI guidelines support moderate-intensity statin therapy (pravastatin 40 mg) for patients with eGFR <60 mL/min/1.73 m², which aligns with the maximum allowable dose in severe renal impairment 2. However, you must start lower due to the FDA safety recommendations.
Clinical Context and Evidence
Renal impairment significantly increases the risk of statin-associated myopathy and rhabdomyolysis 1. This is why the conservative dosing approach is mandatory. The FDA label emphasizes that pravastatin AUCs increase by 25-50% in patients with renal dysfunction, though this data primarily comes from elderly patients 1.
Research supports statin use in this population. The MEGA Study showed that low-dose pravastatin (10-20 mg) in patients with moderate CKD (eGFR 30-60) reduced CHD by 48%, stroke by 73%, and total mortality by 51% 3. Another analysis demonstrated pravastatin 40 mg reduced the rate of kidney function loss by approximately 34% in patients with moderate CKD 4.
Monitoring Requirements
Monitor aggressively for myopathy development:
- Baseline creatine kinase (CK) before starting
- Educate patient to report unexplained muscle pain, tenderness, or weakness immediately
- Check CK if symptoms develop
- Assess lipid response at 4 weeks, then adjust if needed (within the 10-40 mg range) 1
- Monitor renal function periodically - pravastatin may actually slow GFR decline 4, 3
Critical Pitfalls to Avoid
Do not start at 40 mg despite this being the "moderate-intensity" dose recommended by guidelines - the severe renal impairment mandates the 10 mg starting dose per FDA labeling 1. The guideline recommendations assume normal dosing adjustments for renal impairment have been made.
Do not use pravastatin 80 mg - this exceeds the maximum safe dose in severe renal impairment and is generally not recommended even in normal renal function 1.
Do not combine with fibrates in CKD patients, as this substantially increases myopathy risk 5.
If the patient cannot achieve LDL goals on pravastatin 40 mg, consider switching to an alternative LDL-lowering strategy rather than exceeding the maximum dose 1. Options include adding ezetimibe or considering a different statin with better potency at renally-safe doses.
Special Considerations
The patient's age matters - if elderly (≥65 years), this compounds the myopathy risk alongside the renal impairment 1. Be even more vigilant with monitoring in this scenario.
Recent evidence suggests statins reduce all-cause mortality in CKD patients ≥50 years (HR 0.82), supporting their use despite the need for dose adjustment 6. The cardiovascular benefit outweighs the increased monitoring burden in most cases.